Research ArticleBasic Science Investigations
(2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy
Ana P. Kiess, Il Minn, Ganesan Vaidyanathan, Robert F. Hobbs, Anders Josefsson, Colette Shen, Mary Brummet, Ying Chen, Jaeyeon Choi, Eftychia Koumarianou, Kwamena Baidoo, Martin W. Brechbiel, Ronnie C. Mease, George Sgouros, Michael R. Zalutsky and Martin G. Pomper
Journal of Nuclear Medicine October 2016, 57 (10) 1569-1575; DOI: https://doi.org/10.2967/jnumed.116.174300
Ana P. Kiess
1Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
Il Minn
2Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland
Ganesan Vaidyanathan
3Department of Radiology, Duke University Medical Center, Durham, North Carolina; and
Robert F. Hobbs
1Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
Anders Josefsson
2Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland
Colette Shen
1Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
Mary Brummet
2Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland
Ying Chen
2Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland
Jaeyeon Choi
3Department of Radiology, Duke University Medical Center, Durham, North Carolina; and
Eftychia Koumarianou
3Department of Radiology, Duke University Medical Center, Durham, North Carolina; and
Kwamena Baidoo
4Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
Martin W. Brechbiel
4Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
Ronnie C. Mease
2Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland
George Sgouros
1Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
2Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland
Michael R. Zalutsky
3Department of Radiology, Duke University Medical Center, Durham, North Carolina; and
Martin G. Pomper
1Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
2Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 57, Issue 10
October 1, 2016
(2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy
Ana P. Kiess, Il Minn, Ganesan Vaidyanathan, Robert F. Hobbs, Anders Josefsson, Colette Shen, Mary Brummet, Ying Chen, Jaeyeon Choi, Eftychia Koumarianou, Kwamena Baidoo, Martin W. Brechbiel, Ronnie C. Mease, George Sgouros, Michael R. Zalutsky, Martin G. Pomper
Journal of Nuclear Medicine Oct 2016, 57 (10) 1569-1575; DOI: 10.2967/jnumed.116.174300
(2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy
Ana P. Kiess, Il Minn, Ganesan Vaidyanathan, Robert F. Hobbs, Anders Josefsson, Colette Shen, Mary Brummet, Ying Chen, Jaeyeon Choi, Eftychia Koumarianou, Kwamena Baidoo, Martin W. Brechbiel, Ronnie C. Mease, George Sgouros, Michael R. Zalutsky, Martin G. Pomper
Journal of Nuclear Medicine Oct 2016, 57 (10) 1569-1575; DOI: 10.2967/jnumed.116.174300
Jump to section
Related Articles
Cited By...
- Development and Preclinical Evaluation of [211At]PSAt-3-Ga: An Inhibitor for Targeted {alpha}-Therapy of Prostate Cancer
- A Realistic Multiregion Mouse Kidney Dosimetry Model to Support the Preclinical Evaluation of Potential Nephrotoxicity of Radiopharmaceutical Therapy
- Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose 211At-Labeled Anti-HER2 Single-Domain Antibody Fragment
- Glypican-3-Targeted 227Th {alpha}-Therapy Reduces Tumor Burden in an Orthotopic Xenograft Murine Model of Hepatocellular Carcinoma
- An Improved 211At-Labeled Agent for PSMA-Targeted {alpha}-Therapy
- Preclinical Evaluation of 213Bi- and 225Ac-Labeled Low-Molecular-Weight Compounds for Radiopharmaceutical Therapy of Prostate Cancer
- Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer
- Preclinical Evaluation of 203/212Pb-Labeled Low-Molecular-Weight Compounds for Targeted Radiopharmaceutical Therapy of Prostate Cancer
- A Single Dose of 225Ac-RPS-074 Induces a Complete Tumor Response in an LNCaP Xenograft Model
- {alpha}-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies--Part 2
- Targeted {alpha}-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
- Targeted {alpha}-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding
- Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer
- The Future of Radioligand Therapy: {alpha}, {beta}, or Both?